November 24, 2020

The Niche

Knoepfler lab stem cell blog

Astellas Pharma

1 min read

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for a long list of diseases.” The day after hearing the news, I myself feel a bit more optimistic that Astellas will continue this important work and help patients with …Read More

2 min read

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul Wotton, Ph.D., President and CEO, Ocata said, “I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients …Read More